This clinical trial aims to investigate whether thoracic duct ligation (TDL) can improve obesity and lipid metabolism. The primary questions it seeks to answer are:
Whether thoracic duct ligation can improve BMI and lipid metabolism in obese patients.
The safety and feasibility of thoracic duct ligation as a treatment for obesity.
Age & Gender: Individuals aged 18-75 years, regardless of gender.
Clinical Profile:Diagnosed with early-stage lung cancer (stage IA1-IB) and obesity (BMI ≥28 kg/m²).
Scheduled to undergo video-assisted thoracoscopic surgery (VATS) for right-sided lung cancer resection at our institution between October 2024 and October 2026.
Surgical Eligibility: Approved for surgery following multidisciplinary team (MDT) assessment.
Concurrent Thoracic Infections: Patients with active intrathoracic infectious diseases (e.g., inflammatory conditions, tuberculosis).
Refusal of Novel Technique: Patients unwilling to undergo intraoperative thoracic duct ligation.
Clinically Unstable Comorbidities: Severe, unstable cardiovascular, renal, or respiratory disorders.
Prior Bariatric Surgery: History of weight-loss surgery (e.g., gastric bypass, sleeve gastrectomy).
Yongxin Zhou
Lead sponsor
Shanghai Tongji Hospital, Tongji University School of Medicine
Sponsor institution